Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies ​are expected to go public amid a ...

For speculative investors, the start of each year is always a good time to revisit an initial public offering (IPO) calendar.

Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign the public markets are ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 ...

Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments.

Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare ...

Backed by Eli Lilly, Aktis Oncology's $318M IPO marks 2026's first major biotech public offering, signaling renewed investor ...